MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe…
MaaT PharmaJanuary 13, 2022
Ce communiqué ne peut être distribué directement ou indirectement aux Etats-Unis d’Amérique, au Canada, en…
MaaT PharmaJanuary 3, 2022
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013…
MaaT PharmaDecember 11, 2021
MaaT Pharma S.A. (« MaaT Pharma » ou la « Société »), société française de…
MaaT PharmaDecember 6, 2021
This announcement is not being made in and copies of it shall not be distributed…
MaaT PharmaDecember 6, 2021
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results…
MaaT PharmaDecember 1, 2021
Not for release, publication or distribution, in whole or in part, directly or indirectly in…
MaaT PharmaNovember 16, 2021
Ce communiqué ne peut être publié, distribué ou diffusé, directement ou indirectement, aux Etats-Unis d’Amérique,…
MaaT PharmaNovember 16, 2021
Results from HERACLES trial in 24 patients with GI-predominant, steroid-resistant grade III-IV aGvHD and from…
MaaT PharmaNovember 9, 2021
